BDBM230130 US10106559, Example 61::US10435415, Example 61::US9334290, 60::US9334290, 61::US9334290, 62::US9850258, Example 61

SMILES Cn1c2c(F)cccc2c(=O)n(-c2cccc(c2Cl)-c2c(F)cc(C(N)=O)c3[nH]c4cc(ccc4c23)C(C)(C)O)c1=O

InChI Key InChIKey=CACKWDPMBIYJAG-UHFFFAOYSA-N

Data  22 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 22 hits for monomerid = 230130   

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 0.180nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 0.180nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 0.180nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2017
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 0.410nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2017
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 1.40nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 1.40nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2017
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 1.40nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 1.40nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 1.5nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 1.5nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 1.5nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 270nMpH: 7.4 T: 2°CAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substrates ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2017
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 270nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 270nMAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 1.90E+3nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 1.90E+3nMAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 1.90E+3nMAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 1.90E+3nMpH: 7.4 T: 2°CAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substrates ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2017
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 2.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 2.00E+3nMAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 2.00E+3nMAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230130(US9334290, 61 | US9334290, 62 | US9334290, 60 | US...)
Affinity DataIC50: 2.00E+3nMpH: 7.4 T: 2°CAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substrates ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2017
Entry Details
US Patent